Status:
WITHDRAWN
Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
Genzyme, a Sanofi Company
Conditions:
Ischemia Reperfusion Injury
Heart Transplantation
Eligibility:
All Genders
Up to 21 years
Phase:
NA
Brief Summary
The restoration of normal blood flow following a period of ischemia may result in ischemia / reperfusion injury (I/RI), which is characterized by inflammation and oxidative damage to tissues. Varying ...
Eligibility Criteria
Inclusion
- Pediatric population (ages 0-21 years)
- End-stage cardiac disease requiring heart transplantation
- Approval for listing by the UCLA Heart Transplant Committee
Exclusion
- Prior documented Thymoglobulin allergy/adverse reaction
- History of or current diagnosis of lymphoma
- Documented lymphopenia
- Documented Thrombocytopenia
- Pregnancy
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00709293
Start Date
July 1 2008
Last Update
June 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mattel Children's Hospital at UCLA
Los Angeles, California, United States, 90095